Literature DB >> 14716073

Clinical and immunologic components of sarcoidosis.

Andrea T Borchers1, Calvin So, Stanley M Naguwa, Carl L Keen, M Eric Gershwin.   

Abstract

Sarcoidosis is a multisystem granulomatous disease of unknown etiology that affects the lungs and the lymphatic system. It is seen by specialists in allergy, rheumatology, and pulmonary disease. Although there are no clues to etiology, an environmental basis has been implicated primarily on the basis of epidemiologic and anecdotal data. The majority of patients are very readily diagnosed and should not be confused with other pulmonary disorders. Sarcoidosis can become an issue if it occurs in the presence of other significant pulmonary disease, such as patients with asthma or hypersensitivity pneumonitis. Most patients remain asymptomatic and many are diagnosed when picked up on a routine screening exam. Steroids can be used to manage some patients but caution should be exercised to choose the appropriate dose and to treat patients for a limited period of time to avoid the complications of steroids. A minority of patients do progress to significant disease, including morbidity and mortality, and further research is needed to determine more appropriate and specific therapy for such situations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14716073     DOI: 10.1385/CRIAI:25:3:289

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  85 in total

Review 1.  Treatment of sarcoidosis -- from a basic science point of view.

Authors:  D R Moller
Journal:  J Intern Med       Date:  2003-01       Impact factor: 8.989

Review 2.  T-lymphocytes and cytokines in sarcoidosis.

Authors:  Carlo Agostini; Alessia Meneghin; Gianpietro Semenzato
Journal:  Curr Opin Pulm Med       Date:  2002-09       Impact factor: 3.155

Review 3.  Corticosteroid therapy in pulmonary sarcoidosis: a systematic review.

Authors:  Shanthi Paramothayan; Paul W Jones
Journal:  JAMA       Date:  2002-03-13       Impact factor: 56.272

4.  Course and prognosis of sarcoidosis around the world.

Authors:  L E Siltzbach; D G James; E Neville; J Turiaf; J P Battesti; O P Sharma; Y Hosoda; R Mikami; M Odaka
Journal:  Am J Med       Date:  1974-12       Impact factor: 4.965

5.  The mode of presentation of sarcoidosis in Finland and Hokkaido, Japan. A comparative analysis of 571 Finnish and 686 Japanese patients.

Authors:  A Pietinalho; M Ohmichi; Y Hiraga; A B Löfroos; O Selroos
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  1996-09       Impact factor: 0.670

6.  Early treatment of stage II sarcoidosis improves 5-year pulmonary function.

Authors:  Anne Pietinalho; Pentti Tukiainen; Tari Haahtela; Tore Persson; Olof Selroos
Journal:  Chest       Date:  2002-01       Impact factor: 9.410

Review 7.  Is there a role for microorganisms in the pathogenesis of sarcoidosis?

Authors:  R M du Bois; N Goh; D McGrath; P Cullinan
Journal:  J Intern Med       Date:  2003-01       Impact factor: 8.989

8.  Human leukocyte antigen-DRB1 position 11 residues are a common protective marker for sarcoidosis.

Authors:  P J Foley; D S McGrath; E Puscinska; M Petrek; V Kolek; J Drabek; P A Lympany; P Pantelidis; K I Welsh; J Zielinski; R M du Bois
Journal:  Am J Respir Cell Mol Biol       Date:  2001-09       Impact factor: 6.914

9.  HLA-DQB1*0201: a marker for good prognosis in British and Dutch patients with sarcoidosis.

Authors:  Hiroe Sato; Jan C Grutters; Panagiotis Pantelidis; A Neil Mizzon; Tariq Ahmad; Arend-Jan Van Houte; Jan-Willem J Lammers; Jules M M Van Den Bosch; Kenneth I Welsh; Roland M Du Bois
Journal:  Am J Respir Cell Mol Biol       Date:  2002-10       Impact factor: 6.914

Review 10.  Sarcoidosis: immunopathogenetic concepts and their clinical application.

Authors:  J Müller-Quernheim
Journal:  Eur Respir J       Date:  1998-09       Impact factor: 16.671

View more
  1 in total

1.  Endotoxin markers in bronchoalveolar lavage fluid of patients with interstitial lung diseases.

Authors:  Bogumiła Szponar; Lennart Larsson; Joanna Domagała-Kulawik
Journal:  Multidiscip Respir Med       Date:  2012-12-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.